AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Dynein light chain Tctex-type protein 2B

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q8WW35

UPID:

DYT2B_HUMAN

Alternative names:

Tctex1 domain-containing protein 2

Alternative UPACC:

Q8WW35; A6NCN5

Background:

Dynein light chain Tctex-type protein 2B, also known as Tctex1 domain-containing protein 2, plays a crucial role in the cytoplasmic dynein 2 complex. This complex is essential for the movement of cargos along microtubules within cilia and flagella, working in harmony with the intraflagellar transport system. It is specifically required for proper retrograde ciliary transport, highlighting its significance in cellular functionality and structure.

Therapeutic significance:

The protein's involvement in Short-rib thoracic dysplasia 17 with or without polydactyly, a condition characterized by a range of skeletal and organ anomalies, underscores its potential as a target for therapeutic intervention. Understanding the role of Dynein light chain Tctex-type protein 2B could open doors to potential therapeutic strategies, offering hope for conditions associated with ciliopathies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.